Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-4612.13%
operating margin TTM
-4974.27%
revenue TTM
5.94 Million
revenue per share TTM
0.08$
valuation ratios | |
|---|---|
| pe ratio | -9.84 |
| peg ratio | 0.81 |
| price to book ratio | 5.85 |
| price to sales ratio | 442.32 |
| enterprise value multiple | -9.76 |
| price fair value | 5.85 |
profitability ratios | |
|---|---|
| gross profit margin | -943.96% |
| operating profit margin | -4974.27% |
| pretax profit margin | -4598.59% |
| net profit margin | -4612.13% |
| return on assets | -54.63% |
| return on equity | -55.81% |
| return on capital employed | -63.09% |
liquidity ratios | |
|---|---|
| current ratio | 13.13 |
| quick ratio | 13.13 |
| cash ratio | 4.77 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 66.72 |
| days of payables outstanding | 18.11 |
| cash conversion cycle | 48.61 |
| receivables turnover | 5.47 |
| payables turnover | 20.15 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.01 |
| debt equity ratio | 0.01 |
| long term debt to capitalization | 0.01 |
| total debt to capitalization | 0.01 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -35.14 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.53 |
| cash per share | 6.93 |
| operating cash flow per share | -3.52 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -35.14 |
| short term coverage ratios | -182.19 |
| capital expenditure coverage ratio | -349.33 |
Frequently Asked Questions
When was the last time Xenon Pharmaceuticals Inc. (NASDAQ:XENE) reported earnings?
Xenon Pharmaceuticals Inc. (XENE) published its most recent earnings results on 03-11-2025.
What is Xenon Pharmaceuticals Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Xenon Pharmaceuticals Inc. (NASDAQ:XENE)'s trailing twelve months ROE is -55.81%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Xenon Pharmaceuticals Inc. (XENE) currently has a ROA of -54.63%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did XENE's net profit margin stand at?
XENE reported a profit margin of -4612.13% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is XENE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 13.13 in the most recent quarter. The quick ratio stood at 13.13, with a Debt/Eq ratio of 0.01.